NCT00409292View on ClinicalTrials.gov

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

May 31, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

RAD001

Taken orally daily for as long as the participant continues to receive a benefit.

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00409292 - RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter